Close



Mar 28, 2024 08:30PM
Jan 21, 2024 07:30PM
Jan 16, 2024 12:09AM
Nov 14, 2023 08:08PM
Oct 26, 2023 10:16PM
Sep 12, 2023 11:51PM
Aug 29, 2023 08:11AM InnoCare Releases 2023 Interim Results and Business Highlights
Jun 15, 2023 08:30PM
Jun 11, 2023 08:30PM
May 1, 2023 08:30PM
Apr 19, 2023 11:31PM
Feb 6, 2023 07:30PM
Dec 27, 2022 07:30PM
Dec 20, 2022 07:30PM InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Orelabrutinib in Combination with Tafasitamab + Lenalidomide in China
Nov 22, 2022 01:09AM
Nov 7, 2022 07:30PM
Sep 8, 2022 07:39PM
Sep 6, 2022 12:27AM
Aug 30, 2022 08:30PM
Aug 12, 2022 01:45AM
Jul 21, 2022 09:00PM InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Boao Hope City’s Early Access Program
Jun 5, 2022 08:30PM
May 25, 2022 09:15PM
Mar 22, 2022 08:08PM
Mar 13, 2022 08:30PM
Feb 22, 2022 04:09AM
Dec 13, 2021 11:50PM
Dec 2, 2021 09:13PM InnoCare Announces Inclusion of Orelabrutinib in China National Reimbursement Drug List
Nov 14, 2021 07:30PM
Nov 9, 2021 12:06AM
Aug 30, 2021 08:30PM
Aug 29, 2021 07:49AM
Aug 16, 2021 07:00PM
Jun 28, 2021 04:02AM
Jun 16, 2021 11:31PM InnoCare Announces Orphan Drug Designation of Gunagrabtinib by US FDA for Treatment of Cholangiocarcinoma
Mar 26, 2021 07:39AM
Feb 28, 2021 08:48PM
Feb 5, 2021 05:48AM
Nov 2, 2020 02:59AM

251,762 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All